SG11201806622PA - Egfl6 specific monoclonal antibodies and methods of their use - Google Patents

Egfl6 specific monoclonal antibodies and methods of their use

Info

Publication number
SG11201806622PA
SG11201806622PA SG11201806622PA SG11201806622PA SG11201806622PA SG 11201806622P A SG11201806622P A SG 11201806622PA SG 11201806622P A SG11201806622P A SG 11201806622PA SG 11201806622P A SG11201806622P A SG 11201806622PA SG 11201806622P A SG11201806622P A SG 11201806622PA
Authority
SG
Singapore
Prior art keywords
international
egfl6
pearland
pct
monoclonal antibodies
Prior art date
Application number
SG11201806622PA
Inventor
Ningyan Zhang
Zhiqiang An
Anil Sood
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of SG11201806622PA publication Critical patent/SG11201806622PA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6843—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57449—Specifically defined cancers of ovaries
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/136807 Al 10 August 2017 (10.08.2017) WIPO I PCT 111111 11111111 0 111011111111111 010 11111 01110111 011111111110 111111111111E1111 0111111 W O 20 17 / 136807 Al FIG. 1 (51) International Patent Classification: 9618 3 9 / 3 95 (2006.01) C07K 16/28 (2006.01) C07K 16/30 (2006.01) 0078 16/22 (2006.01) (21) International Application Number: PCT/US2017/016659 (22) International Filing Date: 6 February 2017 (06.02.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/291,987 5 February 2016 (05.02.2016) US (71) Applicant: THE BOARD OF REGENTS OF THE UNI- VERSITY OF TEXAS SYSTEM [US/US]; 201 West 7th Street, Austin, TX 78701 (US). (72) Inventors: ZHANG, Ningyan; 3618 Abbeywood Dr., Pearland, TX 77584 (US). AN, Zhigiang; 3618 Abbey- wood Dr., Pearland, TX 77584 (US). SOOD, Anil, K.; 2719 Lakecrest Dr., Pearland, TX 77584 (US). (74) Agent: BYRD, Marshall, P.; Parker Highlander PLLC, 1120 S. Capital of Texas Highway, Building One Suite 200, Austin, TX 78746 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, [Continued on next page] (54) Title: EGFL6 SPECIFIC MONOCLONAL ANTIBODIES AND METHODS OF THEIR USE (57) : Isolated or recombinant anti-EGFL6 monoclonal antibodies are provided. In some cases, antibodies of the embodi- ments can be used for the detection, diagnosis and/or therapeutic treatment of human diseases, such as cancer. WO 2017/136807 Al MIDEDIM011111 1E1 IIIIIMEMOM11111111111111111111111111111110111111111111 SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: — with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))
SG11201806622PA 2016-02-05 2017-02-06 Egfl6 specific monoclonal antibodies and methods of their use SG11201806622PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662291987P 2016-02-05 2016-02-05
PCT/US2017/016659 WO2017136807A1 (en) 2016-02-05 2017-02-06 Egfl6 specific monoclonal antibodies and methods of their use

Publications (1)

Publication Number Publication Date
SG11201806622PA true SG11201806622PA (en) 2018-09-27

Family

ID=59501106

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201806622PA SG11201806622PA (en) 2016-02-05 2017-02-06 Egfl6 specific monoclonal antibodies and methods of their use

Country Status (12)

Country Link
US (2) US10875912B2 (en)
EP (1) EP3411070A4 (en)
JP (3) JP2019512210A (en)
KR (1) KR20180105704A (en)
CN (2) CN113912717B (en)
AU (2) AU2017214685B2 (en)
BR (1) BR112018015826A2 (en)
CA (1) CA3012696A1 (en)
MX (1) MX2018009499A (en)
SG (1) SG11201806622PA (en)
WO (1) WO2017136807A1 (en)
ZA (1) ZA201805051B (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3411070A4 (en) * 2016-02-05 2019-11-27 The Board of Regents of The University of Texas System Egfl6 specific monoclonal antibodies and methods of their use
US11578121B2 (en) * 2017-10-01 2023-02-14 Taipei Medical University Anti-EGF like domain multiple 6 (EGFL6) antibodies
JP2022515543A (en) * 2018-12-30 2022-02-18 エフ．ホフマン－ラ ロシュ アーゲー Anti-rabbit CD19 antibody and how to use
CN110951733A (en) * 2019-11-27 2020-04-03 山西医科大学 siRNA for targeted inhibition of esophageal cancer EGFL6 gene expression, constructed expression vector and application
CN116381251B (en) * 2023-03-13 2024-06-25 柏定生物工程(北京)有限公司 Tumor marker diagnosis kit and diagnosis method thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69526636T3 (en) * 1994-07-29 2006-11-23 Innogenetics N.V. PURIFIED HEPATITIS C-VIRUS WRAPPER PROTEINS FOR DIAGNOSTIC AND THERAPEUTIC USE
US20030036508A1 (en) * 1997-11-22 2003-02-20 John Ford EGF motif protein, EGFL6 materials and methods
AU2002213259A1 (en) * 2000-10-13 2002-04-22 Hyseq, Inc. Egf motif protein, egfl6 materials and methods
EP2471936A3 (en) * 2005-11-24 2013-04-24 The Research Foundation for Microbial Diseases of Osaka University Recombinant polyvalent vaccine
AR059851A1 (en) * 2006-03-16 2008-04-30 Genentech Inc ANTIBODIES OF EGFL7 AND METHODS OF USE
CA2727839C (en) * 2008-06-25 2018-11-20 Esbatech, An Alcon Biomedical Research Unit Llc Stable and soluble antibodies inhibiting vegf
WO2011137334A1 (en) * 2010-04-30 2011-11-03 The Research Foundation Of State University Of New York Compositions and methods for stimulating immune response against moraxella catarrhalis
SG11201400879SA (en) * 2011-09-23 2014-04-28 Technophage Investigação E Desenvolvimento Em Biotecnologia Sa Anti-tumor necrosis factor-alpha agents and uses thereof
US9850300B2 (en) * 2013-03-15 2017-12-26 The Regents Of The University Of Michigan Compositions and methods relating to inhibiting cancer cell growth and/or proliferation
CA2913052A1 (en) 2013-05-24 2014-11-27 Board Of Regents, The University Of Texas System Chimeric antigen receptor-targeting monoclonal antibodies
EP3411070A4 (en) * 2016-02-05 2019-11-27 The Board of Regents of The University of Texas System Egfl6 specific monoclonal antibodies and methods of their use

Also Published As

Publication number Publication date
AU2024203614A1 (en) 2024-06-20
CN113912717A (en) 2022-01-11
JP7358426B2 (en) 2023-10-10
MX2018009499A (en) 2019-05-06
AU2017214685B2 (en) 2024-03-07
KR20180105704A (en) 2018-09-28
CN113912717B (en) 2024-05-03
AU2017214685A1 (en) 2018-08-09
US20210130450A1 (en) 2021-05-06
RU2018131611A (en) 2020-03-05
CN109562163A (en) 2019-04-02
JP2019512210A (en) 2019-05-16
WO2017136807A1 (en) 2017-08-10
BR112018015826A2 (en) 2019-01-02
JP2022008309A (en) 2022-01-13
RU2018131611A3 (en) 2020-05-19
JP2023130411A (en) 2023-09-20
EP3411070A4 (en) 2019-11-27
CN109562163B (en) 2022-04-08
ZA201805051B (en) 2023-05-31
CA3012696A1 (en) 2017-08-10
US20190031751A1 (en) 2019-01-31
US10875912B2 (en) 2020-12-29
EP3411070A1 (en) 2018-12-12

Similar Documents

Publication Publication Date Title
SG11201907753TA (en) Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201811003PA (en) Anti-pd-l1 antibodies and uses thereof
SG11201810023QA (en) Anti-tim-3 antibodies and methods of use thereof
SG11201811432WA (en) Rna for cancer therapy
SG11201807176XA (en) TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201906192SA (en) Methods of treating cancer with anti-pd-1 antibodies
SG11201805709RA (en) Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201808622SA (en) Chimeric receptors to flt3 and methods of use thereof
SG11201806496SA (en) Antigen binding proteins that bind pd-l1
SG11201903882VA (en) Il-2 variants for the treatment of autoimmune diseases
SG11201804787UA (en) Human immunodeficiency virus neutralizing antibodies
SG11201809344QA (en) Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde
SG11201811564QA (en) Methods of treating ovarian cancer
SG11201804178YA (en) Pd1 and/or lag3 binders
SG11201804673WA (en) Novel anti-claudin antibodies and methods of use
SG11201811431VA (en) Multispecific antibodies against cd40 and cd137
SG11201810525XA (en) Anti-gitr antibodies and uses thereof
SG11201806322QA (en) Maytansinoid derivatives, conjugates thereof, and methods of use
SG11201803703UA (en) Anti-complement factor c1q fab fragments and uses thereof
SG11201806622PA (en) Egfl6 specific monoclonal antibodies and methods of their use
SG11201810927QA (en) Pd-l1-specific antibodies and methods of using the same
SG11201809374VA (en) Cd40l-fc fusion polypeptides and methods of use thereof
SG11201908056QA (en) Anti-par2 antibodies and uses thereof
SG11201901020RA (en) Anti-siglec-7 antibodies for the treatment of cancer
SG11201908326YA (en) Methods of treating neurodegenerative diseases